(Q46393134)

21 December 2017

title

Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis (English)

1 reference

21 December 2017

0 references

0 references

1 reference

Aweeka FT

1

1 reference

21 December 2017

Gambertoglio JG

2

1 reference

21 December 2017

Kramer F

3

1 reference

21 December 2017

van der Horst C

4

1 reference

21 December 2017

Polsky B

5

1 reference

21 December 2017

Jayewardene A

6

1 reference

21 December 2017

Lizak P

7

1 reference

21 December 2017

Emrick L

8

1 reference

21 December 2017

Tong W

9

1 reference

21 December 2017

Jacobson MA

10

1 reference

21 December 2017

language of work or name

English

0 references

publication date

1 April 1995

1 reference

21 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

21 December 2017

volume

57

1 reference

21 December 2017

issue

4

1 reference

21 December 2017

page(s)

403-412

1 reference

21 December 2017

Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis

cites work

1 reference

https://api.crossref.org/works/10.1016%2F0009-9236%2895%2990209-0

Prevalence of Resistance in Patients Receiving Ganciclovir for Serious Cytomegalovirus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0009-9236%2895%2990209-0

Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0009-9236%2895%2990209-0

Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0009-9236%2895%2990209-0

Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0009-9236%2895%2990209-0

Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0009-9236%2895%2990209-0

Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0009-9236%2895%2990209-0

Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0009-9236%2895%2990209-0

Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0009-9236%2895%2990209-0

Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0009-9236%2895%2990209-0

Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0009-9236%2895%2990209-0

Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0009-9236%2895%2990209-0

10.1016/0009-9236(95)90209-0

21 January 2018

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017